Verch T - Search Results

1

Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.

Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, Goedegebuure P, Hellstrom KE. Hellstrom I, et al. Among authors: verch t. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1520-6. doi: 10.1158/1055-9965.EPI-08-0039. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18559570

2

Mesothelin variant 1 is released from tumor cells as a diagnostic marker.

Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE. Hellstrom I, et al. Among authors: verch t. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20. doi: 10.1158/1055-9965.EPI-05-0334. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16702385

3

MESOMARK: a potential test for malignant pleural mesothelioma.

Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY. Beyer HL, et al. Among authors: verch t. Clin Chem. 2007 Apr;53(4):666-72. doi: 10.1373/clinchem.2006.079327. Epub 2007 Feb 8. Clin Chem. 2007. PMID: 17289801 Clinical Trial.

4

Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab.

Yin KC, Chen D, Bakhtiar R, Verch T. Yin KC, et al. Among authors: verch t. Bioanalysis. 2011 Sep;3(18):2107-17. doi: 10.4155/bio.11.208. Bioanalysis. 2011. PMID: 21942521

5

MESOMARK(®) in vitro diagnostic test for mesothelioma.

Li ZQ, Verch T, Allard WJ. Li ZQ, et al. Among authors: verch t. Expert Opin Med Diagn. 2007 Sep;1(1):137-42. doi: 10.1517/17530059.1.1.137. Expert Opin Med Diagn. 2007. PMID: 23489276

6

Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.

Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN, Aerts J. Hegmans JP, et al. Among authors: verch t, t jampens d. Technol Cancer Res Treat. 2009 Oct;8(5):323-32. doi: 10.1177/153303460900800502. Technol Cancer Res Treat. 2009. PMID: 19754208 Free article.

7

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr. Moore RG, et al. Among authors: verch t. Gynecol Oncol. 2008 Feb;108(2):402-8. doi: 10.1016/j.ygyno.2007.10.017. Epub 2007 Dec 3. Gynecol Oncol. 2008. PMID: 18061248

8

Mitigation of microtiter plate positioning effects using a block randomization scheme.

Roselle C, Verch T, Shank-Retzlaff M. Roselle C, et al. Among authors: verch t. Anal Bioanal Chem. 2016 Jun;408(15):3969-79. doi: 10.1007/s00216-016-9469-0. Epub 2016 Apr 26. Anal Bioanal Chem. 2016. PMID: 27116421

9

Validation of preclinical pharmacokinetic and immunogenicity assays for an anti-PCSK9 antibody.

Chilewski SD, Follmer T, Ansbro F, Chen D, Zhao Q, Teyral J, Bakhtiar R, Verch T. Chilewski SD, et al. Among authors: verch t. J Immunoassay Immunochem. 2011;32(4):296-317. doi: 10.1080/15321819.2011.569046. J Immunoassay Immunochem. 2011. PMID: 21728822

10

Miniaturized immunoassays: moving beyond the microplate.

Verch T, Bakhtiar R. Verch T, et al. Bioanalysis. 2012 Jan;4(2):177-88. doi: 10.4155/bio.11.301. Bioanalysis. 2012. PMID: 22250800 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters